GamaMabs' lead project is the monoclonal antibody (mAb) GM102, which targets anti-müllerian human receptor II, an unaddressed specific target in cancer.

The company develops low-fucose EMABling antibodies with increased tumor cell killing properties through the activation of immune system cells.

GamaMabs has a licensing agreement with MedImmune to develop an antibody drug conjugate targeting cancer.

The company was founded in 2013 in France.